Bronchialkarzinom

Titel
Studie
Jahr

Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Schulz, H., Janssen, J., Chiabudini, M., Koszinowski, S., Potthoff, K., Lang, S., Runkel, E., 2018.

Oncol Res Treat 41 (suppl 4)(P912).

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NEPTUN
2018

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

Schuette, W., Schirmacher, P., Eberhardt, W.E.E., Dietel, M., Zirrgiebel, U., Muehlenhoff, L., Thomas, M., 2018.

BMC Cancer 18, 135. doi:10.1186/s12885-018-4032-3

Indikation: Bronchialkarzinom; Veranstaltung: -; Journal: BMC Cancer

REASON
2018

Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Losem, C., Ketzler-Henkel, Zahn, M., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., deWit, M., Metzenmacher, M., Waller, C., Kern, J., Weichert, W., Sebastian, M., Thomas, M., 2017.

IASLC World Conference (Yokohama) (P3.01-088).

Indikation: Bronchialkarzinom; Veranstaltung: IASLC (WCLC); Journal: -

CRISP
2017

Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Schirmacher, P., Sebastian, M., Thomas, M., 2017.

7th European Lung Cancer Conference (ELCC) (125P).

Indikation: Bronchialkarzinom; Veranstaltung: ELCC (IASLC); Journal: -

CRISP
2017

Cisplatin vs. carboplatin in routine treatment of advanced non-small cell lung cancer – results from the prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P600), 174.

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2017

Clinical Comparison of first-line platin chemotherapy regimens in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) using German registry data.

Haas, J., Meise, D., Ogbonnaya, A., Eaddy, M., Daeßler, K., Sandner, R., Binninger, A., Jaenicke, M., Chiabudini, M., Marschner, N., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Bronchialkarzinom; Veranstaltung: ISPOR; Journal: -

TLK
2017

Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC – results from prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Ann Oncol 28 (suppl 5)(1370P), 490.

Indikation: Bronchialkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TLK
2017

CRISP
2017

Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study.

Verschuer, U. von, Schnell, R., Tessen, H.W., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419-1. doi: 10.1016/j.lungcan.2017.07.031

Indikation: Bronchialkarzinom; Veranstaltung: -; Journal: Lung Cancer

TLK
2017

Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W., Marschner, N., Jänicke, M., Hipper, A., Karatas, A., Sebastian, M., Thomas, M., Schirmacher, P., 2017.

J Thorac Oncol 12(1)(MA08.02), S385. doi:10.1016/j.jtho.2016.11.435

Indikation: Bronchialkarzinom; Veranstaltung: ELCC (IASLC); Journal: Journal of Thoracic Oncology

CRISP
2017

REASON: Klinisch-pathologische Faktoren relevant für die klinische Wirksamkeit von Gefitinib bei Patienten mit NSCLC Stadium IIIb/IV und mutiertem EGF Rezeptor (EGFR-M+).

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin P430.

Indikation: Bronchialkarzinom; Veranstaltung: DGP; Journal: -

REASON
2016

Zielgerichtete Therapie des NSCLC mit Gefitinib in Abhängigkeit von der Art der EGFR-Mutation: Auswertung der klinischen Wirksamkeit in REASON Exon-Subgruppen.

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin P429.

Indikation: Bronchialkarzinom; Veranstaltung: DGP; Journal: -

REASON
2016

REASON: Factors influencing outcome in patients (pts) with NSCLC stage IIIB/IV and mutated EGF receptor (EGFR-M+) treated with gefitinib.

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Oncol Res Treat, 39 (suppl 1) (ID 0345), 120. doi:10.1159/000444354

Indikation: Bronchialkarzinom; Veranstaltung: DKK; Journal: Oncology Research and Treatment

REASON
2016

Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon.

Schuette, W., Dietel, M., Thomas, M., Eberhardt, W., Zirrgiebel, U., Radke, S., Schirmacher, P., 2016.

Oncol Res Treat, 39 (suppl 1), (ID 0341) 120. doi:10.1159/000444354

Indikation: Bronchialkarzinom; Veranstaltung: DKK; Journal: Oncology Research and Treatment

REASON
2016

Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W.E., Marschner, N., Jänicke, M., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Sebastian, M., Thomas, M., 2016.

J Clin Oncol 34 (suppl; abstr TPS9108). doi: 10.1200/JCO.2016.34.15_suppl.TPS9108

Indikation: Bronchialkarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

CRISP
2016

Time to deterioration as measure for symptom burden and quality of life – Data from the LuLife project in 507 patients with non-small cell lung cancer in Germany.

von Verschuer, U., Sandner, R., Tessen, H.-W., Emde, T.-O., Schnitzler, M., Binninger, A., Jänicke, M., Marschner, N., 2016.

Oncol Res Treat 39 (suppl 3)(V986), 303. doi:10.1159/000449050

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2016

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with lung cancer: results from an interim analysis of the non-interventional study NADIR.

Potthoff, K., Lück, A., Frost, N., Losem, C., Weide, R., Schulz, H., 2016.

Oncol Res Treat 39 (suppl3)(P949), 292. doi:10.1159/000449050

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NADIR
2016

Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W.E., Marschner, N., Jänicke, M., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Sebastian, M., Thomas, M., 2016.

Oncol Res Treat 39 (suppl3)(P295), 90. doi:10.1159/000449050

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

CRISP
2016

Do we miss changes in Quality of Life? Data from the LuLife project in patients with non-small cell lung cancer in Germany.

von Verschuer, U., Sandner, R., Däßler, K.-U., Tessen, H.W., Münz, M., Spring, L., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V45), 13. doi:10.1159/000439070

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2015

EGFR mutation testing and treatment with tyrosin-kinase inhibitors in patients with metastatic non-small cell lung cancer treated by office based medical oncologists in Germany – data from the clinical registry on lung cancer (TLK).

Bertram, M., Petersen, V., Heßling, J., Tessen, H.W., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V886), 269. doi:10.1159/000439070

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2015

Final Results from REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in Germany.

Schuette, W., Eberhardt, W., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Zaun, S., Zirrgiebel, U., Thomas, M., 2014.

Oncol Res Treat, Deutscher Krebskongress, Berlin 37 (suppl 1) (ID 209), 89. doi:10.1159/000360634

Indikation: Bronchialkarzinom; Veranstaltung: DKK; Journal: Oncology Research and Treatment

REASON
2014

Prognostic factors for overall survival in patients with advanced NSCLC – data from the clinical registry on lung cancer (TLK).

von Verschuer, U., Tessen, H.W., Eggert, J., Neise, M., Frank, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(V701), 227. doi:10.1159/000368945

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2014

Real-life treatment and outcome data for patients with advanced NSCLC receiving treatments containing bevacizumab – data from the clinical registry on lung cancer (TLK).

Steffens, C.-C., Tessen, H.W., Losem, C., Münz, M., Jänicke, M., Spring, L., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P217), 64. doi:10.1159/000368945

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2014

Overall survival and sequential treatment of patients with advanced NSCLC in German outpatients centres – data from the clinical TLK Registry.

Marschner, N., Bertram, M., Kopfmann, S., von Verschuer, U. von, Tessen, H.W., 2013.

Onkologie 36 (suppl 7)(V118), 29. doi:10.1159/000356365

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TLK
2013

EGFR mutation testing in lung cancer patients of German outpatients centres – data from the clinical TLK Registry.

Tessen, H., Groschek, M., Neise, M., Schnell, R., Kopfmann, S., Hartmann, H., 2012.

Onkologie 35 (suppl 6)(P474), 139. doi:10.1159/000258182

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TLK
2012

Mutation analysis from the REASON, a Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV.

Schirmacher, P., Schuette, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Zaun, S., Dietel, M., 2012.

Indikation: Bronchialkarzinom; Veranstaltung: DGP; Journal: -

REASON
2012

REASON: TKI sensitive EGFR mutation status and associated characteristics of advanced NSCLC patients – Results from a German registry.

Thomas, M., Eberhardt, W., Graf von der Schluenburg, J., Dietel, M., Schirmacher, P., Gutendirf, B., Schaller, F., Schütte, W., 2011.

Onkologie 34 (suppl 6)(V451), 124.

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Onkologie

REASON
2011

EGFR Mutation Status in NSCLC Patients Stage IIIB/IV in Germany – Initial Results from a German Registry.

Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, B., Zirrgiebel, U., Schütte, W., 2011.

EMCC / ESMO, European Multidisciplinary Cancer Congress, Stockholm (Abstract 9015), 596.

Indikation: Bronchialkarzinom; Veranstaltung: EMCC (ESMO); Journal: -

REASON
2011

The treatment of lung cancer in German outpatient centres. Data from a clinical registry – TLK Registry.

Tessen, H.W., Hutzschenreuter, U., Steffens, C.C., Nusch, A., Spirik, J., Marschner, N., 2011.

Onkologie 34 (suppl 6)(P533), 153. doi:10.1159/000333301

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Onkologie

TLK
2011

REASON: A Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV in Germany.

Schuette, W., Eberhardt, W., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, B., Thomas, M., 2011.

Amsterdam; 2011.

Indikation: Bronchialkarzinom; Veranstaltung: WCLC; Journal: -

REASON
2011

EGFR mutation testing and first line treatment of patients with advanced NSCLC and positive EGFR mutation status: results from a German registry.

Eberhardt, W., Thomas, M., Graf von der Schulenburg, J.-M., Dietel, M., Schirmacher, P., Gutendorf, P., Zirrgiebel, U., Schütte, W., 2011.

EMCC / ESMO, European Multidisciplinary Cancer Congress, Stockholm (Poster 133), 664.

Indikation: Bronchialkarzinom; Veranstaltung: EMCC (ESMO); Journal: -

REASON
2011

REASON: A Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV.

Dietel, M., Schütte, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Schirmacher, P., 2011.

Indikation: Bronchialkarzinom; Veranstaltung: DGP; Journal: -

REASON
2011

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com